Security Snapshot

Allogene Therapeutics, Inc. - Common Stock, par value $0.001 per share (the "Shares") (ALLO) Institutional Ownership

CUSIP: 019770106

13F Institutional Holders and Ownership History from Q1 2016 to Q1 2026

Latest Period

Q1 2026

Institutions Reporting

200

Shares (Excl. Options)

181,970,323

Price

$2.44

Save this security page for your next review

Keep this CUSIP in your watchlists so you can revisit quarter changes from one place. If you create an account from here, we will bring you back after verification.

Create free account and return here Sign in and return here Review latest holder period
Type / Class
Equity / Common Stock, par value $0.001 per share (the "Shares")
Symbol
ALLO on Nasdaq
Shares outstanding
244,825,714
Price per share
$2.31
All holders as of 31 Mar 2026
Q1 2026
Total 13F shares
181,970,323
Total reported value
$439,333,278
% of total 13F portfolios
0%
Share change
+20,573,892
Value change
+$56,483,279
Number of holders
200
Price from insider filings
$2.31
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Quick Takeaways

  • ALLO - Allogene Therapeutics, Inc. - Common Stock, par value $0.001 per share (the "Shares") is tracked under CUSIP 019770106.
  • 200 institutions reported positions in Q1 2026.
  • 7 significant owners is listed from Schedule 13D/13G reporting.

What Changed

  • Holder count moved from 170 to 200 between Q4 2025 and Q1 2026.
  • Reported value moved from $222,791,071 to $439,333,278.

Why This Matters

  • You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
  • 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.

Source Evidence

Source: SEC Form 13F

Latest holder context comes from 200 institutions filings for Q1 2026.

Open SEC Evidence

Investment Quick Answers

What is CUSIP 019770106?
CUSIP 019770106 identifies ALLO - Allogene Therapeutics, Inc. - Common Stock, par value $0.001 per share (the "Shares") in SEC 13F datasets.

Where can I see the latest institutional holders?
Review the Q1 2026 holders report and the ownership history table below.

Significant Owners of Allogene Therapeutics, Inc. - Common Stock, par value $0.001 per share (the "Shares") (ALLO) based on Schedule 13D/G filings

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
PFIZER INC 9% $30,183,895 22,032,040 Pfizer Inc. 06 Nov 2025
Frazier Life Sciences Public Fund, L.P. 4.7% $39,540,947 16,205,306 Frazier Life Sciences Public Fund, L.P. 16 Apr 2026
Belldegrun Arie 5.4% -6.7% $32,857,975 +$532,440 13,466,383 +1.6% Arie Belldegrun, M.D. 31 Mar 2026
Chang David D 4.9% -6% $30,005,544 +$478,560 12,297,354 +1.6% David D. Chang, M.D., Ph.D. 31 Mar 2026
BlackRock, Inc. 5.3% $17,633,122 11,450,079 BlackRock, Inc. 31 Mar 2025
FMR LLC 4.9% -58% $15,747,811 -$20,861,062 10,225,851 -57% FMR LLC 28 Feb 2025
CITADEL ADVISORS LLC 2.8% -55% $16,726,493 -$15,838,116 6,855,120 -49% Kenneth Griffin 31 Mar 2026

As of 31 Mar 2026, 200 institutional investors reported holding 181,970,323 shares of Allogene Therapeutics, Inc. - Common Stock, par value $0.001 per share (the "Shares") (ALLO). This represents 74% of the company’s total 244,825,714 outstanding shares.

Top 25 Institutional Shareholders

The largest institutional shareholders of Allogene Therapeutics, Inc. - Common Stock, par value $0.001 per share (the "Shares") (ALLO) together control 61% of the company’s outstanding shares — a level of ownership often associated with strong institutional conviction and long‑term capital commitment.

Institution Ownership % Shares Held Share Change % Portfolio % Holdings Value
Pfizer Inc 9% 22,032,040 0% 21% $49,792,410
BlackRock, Inc. 7.8% 19,091,095 +8% 0% $46,582,273
TPG GP A, LLC 7.6% 18,716,306 0% 1.2% $45,667,787
STATE STREET CORP 3.5% 8,660,306 +214% 0% $21,131,147
PRIMECAP MANAGEMENT CO/CA/ 3.4% 8,379,840 +2.9% 0.02% $20,446,810
VANGUARD CAPITAL MANAGEMENT LLC 2.8% 6,921,350 0% 0% $16,888,094
CITADEL ADVISORS LLC 2.8% 6,793,620 -44% 0.01% $16,576,432
PRICE T ROWE ASSOCIATES INC /MD/ 2.2% 5,380,902 +68% 0% $13,130,000
TWO SIGMA INVESTMENTS, LP 2.2% 5,375,456 +57% 0.01% $13,116,113
GEODE CAPITAL MANAGEMENT, LLC 1.7% 4,124,178 +4.9% 0% $10,065,365
Frazier Life Sciences Management, L.P. 1.6% 3,796,668 -1.9% 0.24% $9,263,870
Woodline Partners LP 1.4% 3,501,078 +0.02% 0.03% $8,542,630
Patient Square Capital LP 1.4% 3,450,000 -30% 1.5% $8,418,000
MARSHALL WACE, LLP 1.4% 3,447,984 +1107% 0.01% $8,413,082
MILLENNIUM MANAGEMENT LLC 1.4% 3,322,053 +80% 0.01% $8,105,809
Candriam S.C.A. 1.2% 2,997,318 +30% 0.04% $7,313,456
Wildcat Capital Management, LLC 1.2% 2,920,787 0% 6.7% $7,126,720
GOLDMAN SACHS GROUP INC 1.1% 2,766,244 +21% 0% $6,749,636
D. E. Shaw & Co., Inc. 1.1% 2,763,776 +115% 0.01% $6,743,613
Boxer Capital Management, LLC 1.1% 2,725,000 0.87% $6,649,000
AQR CAPITAL MANAGEMENT LLC 1% 2,484,780 +74% 0% $6,062,864
Nuveen, LLC 0.95% 2,315,092 +751% 0% $5,648,824
MPM BIOIMPACT LLC 0.92% 2,242,933 0.42% $5,472,757
RENAISSANCE TECHNOLOGIES LLC 0.87% 2,139,328 -2.2% 0.01% $5,219,960
JACOBS LEVY EQUITY MANAGEMENT, INC 0.82% 2,013,508 0.02% $4,912,960

Institutional Holders of Allogene Therapeutics, Inc. - Common Stock, par value $0.001 per share (the "Shares") (ALLO) across Reporting Periods

Period Reported Shares, Excl. Options Value, Excl. Options Value Change Price (Median) Investors
2026 Q1 181,970,323 $439,333,278 +$56,483,279 $2.44 200
2025 Q4 162,692,562 $222,791,071 +$240,755 $1.37 170
2025 Q3 162,089,712 $201,004,443 -$24,367,010 $1.24 167
2025 Q2 183,617,614 $207,883,293 -$15,409,926 $1.13 153
2025 Q1 196,986,783 $288,577,139 +$11,150,657 $1.46 167
2024 Q4 188,657,885 $401,850,158 -$12,907,825 $2.13 170
2024 Q3 164,371,652 $460,365,265 -$1,917,859 $2.80 152
2024 Q2 165,184,059 $384,891,280 +$75,138,227 $2.33 169
2024 Q1 131,205,694 $586,006,096 +$44,997,765 $4.47 158
2023 Q4 122,248,338 $392,448,357 -$24,859,731 $3.21 167
2023 Q3 130,384,371 $413,319,837 -$17,479,237 $3.17 152
2023 Q2 133,404,417 $662,853,148 +$77,627,682 $4.97 168
2023 Q1 117,863,372 $582,311,658 +$28,545,426 $4.94 174
2022 Q4 111,615,016 $701,714,273 +$16,748,007 $6.29 166
2022 Q3 106,389,695 $1,148,387,442 +$56,535,530 $10.80 182
2022 Q2 100,792,050 $1,148,985,365 +$110,979,207 $11.40 155
2022 Q1 91,688,120 $835,872,818 +$16,130,116 $9.11 173
2021 Q4 85,813,394 $1,280,601,899 -$105,097,078 $14.92 168
2021 Q3 86,172,174 $2,214,699,254 +$36,168,155 $25.70 165
2021 Q2 86,340,537 $2,251,293,398 -$84,504,708 $26.08 175
2021 Q1 86,575,661 $3,055,834,294 -$11,800,278 $35.30 167
2020 Q4 87,569,716 $2,210,441,766 +$86,472,875 $25.24 160
2020 Q3 83,175,052 $3,136,521,357 -$164,131,449 $37.71 158
2020 Q2 86,937,058 $3,722,235,026 +$671,195,013 $42.82 170
2020 Q1 73,747,853 $1,390,700,983 +$46,546,025 $19.44 115
2019 Q4 71,621,156 $1,860,741,066 +$73,711,322 $25.98 114
2019 Q3 68,693,966 $1,760,955,637 +$43,711,782 $27.26 94
2019 Q2 68,882,259 $1,691,632,297 +$152,108,493 $26.85 94
2019 Q1 65,390,655 $1,661,573,471 +$80,500,361 $28.91 85
2018 Q4 54,998,315 $1,469,849,010 +$1,469,849,001 $26.93 78
2016 Q2 0 $0 -$115,000 $2.31 0
2016 Q1 4,033 $115,000 $28.51 1
We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Here you can make detailed settings or revoke your consent (in part if necessary) with effect for the future. For further information, please refer to our Privacy Policy .